| STAR and Deferred Stenting Study (NCT05089864) | Saint Luke's Health System | 2021-11-23 |
| COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease (NCT06075602) | Luzerner Kantonsspital | 2021-11-01 |
| SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters (NCT04988685) | Luzerner Kantonsspital | 2021-06-01 |
| Physiology and Residual Ischemia After Percutaneous Coronary Intervention (NCT04494750) | Laval University | 2021-02-18 |
| SELUTION SLR™ 014 In-stent Restenosis (NCT04280029) | M.A. Med Alliance S.A. | 2020-07-06 |
| Treatment of In-Stent Restenosis 2 Study (NCT03667313) | University Hospital Ostrava | 2018-10-01 |
| Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents (NCT04475380) | Foundation of Cardiovascular Research and Education Enschede | 2018-09-21 |
| Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon (NCT03242096) | InnoRa GmbH | 2017-07-21 |
| Restenosis in Coronary Stents And Cutaneous HEaLing (NCT04915391) | Fundación para la Investigación Biosanitaria del Principado de Asturias | 2017-04-25 |
| DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold (NCT03074305) | Samsung Medical Center | 2017-03-08 |
| Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis (NCT02944890) | ZhuHai Cardionovum Medical Device Co., Ltd. | 2016-05-01 |
| Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions (NCT02300454) | Mitsui Memorial Hospital | 2015-06-01 |
| Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR (NCT02474485) | SIS Medical AG | 2015-03-01 |
| Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DES (NCT02367495) | Deutsches Herzzentrum Muenchen | 2015-01-01 |
| EGO-COMBO Clinical End-point Extension Study Beyond 36 Months (NCT02263313) | The University of Hong Kong | 2014-09-01 |
| Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) (NCT02151812) | Hemoteq AG | 2014-08-13 |
| To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels (NCT01977534) | Abbott Medical Devices | 2014-01-01 |
| The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary Lesions (NCT01915420) | Medical Care Center Prof. Mathey, Prof. Schofer, Ltd. | 2013-08-01 |
| XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study (NCT01894152) | Abbott Medical Devices | 2013-07-01 |
| Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis (NCT01967199) | Seung-Jung Park | 2013-04-18 |
| ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients. (NCT01759290) | Abbott Medical Devices | 2013-01-01 |
| Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT) (NCT01674803) | Foundation of Cardiovascular Research and Education Enschede | 2012-12-21 |
| Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis. (NCT01651390) | Biotronik AG | 2012-06-01 |
| ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (NCT01583608) | Medical Care Center Prof. Mathey, Prof. Schofer, Ltd. | 2012-04-01 |
| Safety Study of a Bioresorbable Coronary Stent (NCT01262703) | REVA Medical, Inc. | 2011-12-01 |
| XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study (NCT01249027) | Abbott Medical Devices | 2010-11-01 |
| DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population (NCT01331707) | Foundation of Cardiovascular Research and Education Enschede | 2010-11-01 |
| DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity (NCT02175706) | Thorax Centrum Twente | 2010-11-01 |
| OCT Evaluation of Healing of COMBO Stent (NCT01274234) | Prof. Stephen Lee | 2010-10-01 |
| EXCEL Clinical Trial (Universal Registry) (NCT01205789) | Abbott Medical Devices | 2010-10-01 |
| EXCEL Clinical Trial (NCT01205776) | Abbott Medical Devices | 2010-09-29 |
| XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) (NCT01178268) | Abbott Medical Devices | 2010-08-01 |
| A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population (NCT01115933) | Abbott Medical Devices | 2010-04-01 |
| ABSORB EXTEND Clinical Investigation (NCT01023789) | Abbott Medical Devices | 2010-01-01 |
| XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort (NCT01106534) | Abbott Medical Devices | 2009-08-01 |
| SPIRIT PRIME Clinical Trial (NCT00916370) | Abbott Medical Devices | 2009-06-01 |
| Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period (NCT00882219) | Abbott Medical Devices | 2009-03-01 |
| ABSORB Clinical Investigation, Cohort B (NCT00856856) | Abbott Medical Devices | 2009-03-01 |
| The Effects of Bindarit in Preventing Stent Restenosis (NCT01269242) | Aziende Chimiche Riunite Angelini Francesco S.p.A | 2009-01-01 |
| PIoglitazone for PrEvention of Restenosis in Diabetic Patients (NCT00376870) | University of Rome Tor Vergata | 2008-07-01 |
| XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort) (NCT01120379) | Abbott Medical Devices | 2008-07-01 |
| XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study (NCT00631228) | Abbott Medical Devices | 2008-06-01 |
| Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal (NCT00589810) | The Cleveland Clinic | 2007-08-01 |
| Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial (NCT00500279) | Seoul National University Hospital | 2006-11-01 |
| SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe (NCT00402272) | Abbott Medical Devices | 2006-11-01 |
| SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study) (NCT01171820) | Abbott Medical Devices | 2006-11-01 |
| SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents (NCT00714545) | Scripps Health | 2006-04-01 |
| Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT) (NCT00752362) | Sahajanand Medical Technologies Limited | 2006-03-01 |
| ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation (NCT00300131) | Abbott Medical Devices | 2006-03-01 |
| Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents (NCT00552669) | Centro de estudios en Cardiologia Intervencionista | 2006-01-01 |
| Serp-1 for the Treatment of Acute Coronary Syndrome (NCT00243308) | Viron Therapeutics Inc | 2005-10-01 |
| Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries (NCT00248066) | Sarepta Therapeutics, Inc. | 2005-09-01 |
| Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis (NCT00124943) | Celgene Corporation | 2005-07-01 |
| SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System (NCT00180310) | Abbott Medical Devices | 2005-07-01 |
| Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries (NCT00140101) | Abbott Medical Devices | 2005-05-01 |
| The SCRIPPS DES REAL WORLD Registry (NCT00714623) | Paul S Teirstein, MD | 2005-03-01 |
| PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions (NCT00180466) | Abbott Medical Devices | 2004-10-01 |
| Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries (NCT00148356) | Abbott Medical Devices | 2004-09-01 |
| Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II) (NCT00409981) | University Hospital, Saarland | 2004-07-01 |
| Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty (NCT00162357) | Lantheus Medical Imaging | 2004-04-01 |
| Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR I) (NCT00106587) | University Hospital, Saarland | 2003-12-01 |
| Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis (NCT00287573) | Boston Scientific Corporation | 2003-06-01 |
| Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCI (NCT00412126) | Hamilton Health Sciences Corporation | 2002-07-01 |
| Oral Sirolimus for In-Stent Restenosis (NCT00859183) | Deutsches Herzzentrum Muenchen | 2001-10-01 |
| A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels. (NCT00055510) | Chugai Pharma USA | |